Open Access
Article
Alternative splicing of RAGE: roles in biology and disease
Anastasia Z Kalea1,Ann Marie Schmidt1,Barry I Hudson1
1
Division of Nephrology/Hypertension, Feinberg School of Medicine, Northwestern University, IL, USA
DOI: 10.2741/3884 Volume 16 Issue 7, pp.2756-2770
Published: 01 June 2011
(This article belongs to the Special Issue RAGE signaling)
Abstract

The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

Share and Cite
Anastasia Z Kalea, Ann Marie Schmidt, Barry I Hudson. Alternative splicing of RAGE: roles in biology and disease. Frontiers in Bioscience-Landmark. 2011. 16(7); 2756-2770.